A study to assess the correlation between biochemical indices and severity of COVID-19 infection in patients with type 2 diabetes mellitus
Keywords:Covid-19, Type 2 diabetes, C-reactive protein, Serum ferritin, Serum lactate dehydrogenase
Objective: To describe the relationship between biochemical indices and severity of Covid-19 infection in adults with Type 2 Diabetes. Research design & methods: This was a single centre retrospective study conducted in a tertiary care hospital. The data of adults with Type 2 diabetes admitted with covid 19 infection between July 2020 to January 2021 was analysed. Inflammatory markers like C-reactive protein (CRP), serum ferritin and lactate dehydrogenase (LDH) levels were correlated with severity of covid based on the extent of lung involvement in CT Chest and oxygen saturation at the time of admission. The data was compared between patients who improved and those who succumbed to the illness. Results: 411 adults with type 2 diabetes infected with novel Corona virus were included in the study. Among patients with mild lung involvement, 99.4% had mild covid, 0.6% had moderate covid and none had severe covid whereas, in patients with severe lung involvement 84% had severe covid. The mean LDH, ferritin and CRP in survivors was 318.5 IU/L, 403.8 ng/ml, and 42.7 mg/dl respectively whereas in non survivors, the values were 36.4 IU/L, 991.6 ng/ml, and 172.8 mg/dl respectively. Comparison of CT score with disease outcome revealed 88.4% survival with mild against 7.4% with severe lung involvement. Conclusion: The study highlights the importance of evaluation of inflammatory biomarkers in covid patients with type 2 diabetes, which is helpful in prognostication and identification of disease severity. This will be useful in planning the treatment for better outcomes in this population.
Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020; 14:303–310.
Shenoy A, Ismaily M, Bajaj M. Diabetes and covid-19: a global health challenge. BMJ Open Diabetes Research Care.2020;8(1): e001450. doi:10.1136/bmjdrc-2020–001450.
Angelidi AM, Belanger MJ, Mantzoros CS. COVID-19 and diabetes mellitus: what we know, how our patients should be treated now, and what should happen next. Metabolism. 2020; 107:154245. doi: 10.1016/j.metabol.2020.154245.
Gentile S, Strollo F, Ceriello A. COVID-19 infection in Italian people with diabetes: Lessons learned for our future (an experience to be used). Diabetes Res Clin Pract. 2020; 162:108137. doi: 10.1016/j.diabres.2020.108137.
Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020;318: E736–E741.
Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services, 2020.
Yang JK, Feng Y, Yuan MY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med.2006; 23: 623–628.
WHO, Coronavirus disease (COVID-19) technical guidance. WHO (Accessed on March 4, 2020) Online Version, 2020.
Pearson-Stuttard J, Blundell S, Harris T, Cook DG, Critchley J. Diabetes and infection: assessing the association with glycaemic control in population-based studies. Lancet Diabetes Endocrinol. 2016; 4148–158.
Li S, Wang J, Zhang B, Li X, Liu Y. Diabetes Mellitus and Cause-Specific Mortality: A Population-Based Study. Diabetes Metab J. 2019; 43:319–341.
Hassan DM, Mohammed AM, Bevington J (2019) SMART Population Screening and Management in Qatar. Int J Diabetes Clin Res 6:099. doi.org/10.23937/2377- 3634/1410099.
Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382:1708–1720.
Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARSCoV-2. J Endocrinol Invest. 2020; 43:867–869.
Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(:363–374.
Kohio HP, Adamson AL. Glycolytic control of vacuolartype ATPase activity: a mechanism to regulate influenza viral infection. Virology. 2013; 444:301–309.
Jialin Xiang, Jing Wen, Viaoquing Yuvan. Potential biochemical markers to identify severe cases among COVID-19 patients. BMJ. 2020; 23.
Xu L, Mao Y, Chen G. Risk factors for 2019 novel coronavirus disease (COVID-19) patients progressing to critical illness: a systematic review and metaanalysis. Aging (Albany NY). 2020;12(12):12410–12421. doi:10.18632/aging. 103383
Ji M, Yuan L, Shen W, et al. Characteristics of disease progress in patients with coronavirus disease 2019 in Wuhan, China. Epidemiol Infect. 2020;148: e94. doi:10.1017/S0950268820000977
Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620– 2629. doi:10.1172/JCI137244
Zhang B, Zhou X, Qiu Y, et al. Clinical characteristics of 82 death cases with COVID-19. PLoS One. 2020;15(7): e0235458. doi: 10.1371/journal.pone. 0235458
Hu Y, Zhan C, Chen C, Ai T, Xia L (2020) Chest CT findings related to mortality of patients with COVID-19: A retrospective case-series study. PLoS ONE 15(8): e0237302
How to Cite
Copyright (c) 2022 Dr. Geethanjali J, Pushpa Saravanan, Vasuki R, Dharmarajan P, Periyandavar I
This work is licensed under a Creative Commons Attribution 4.0 International License.
CC BY License